2
Registered trials
2
Recruiting
2
Unique sponsors
2
Unique IMPs
2
Commercial trials
Drug classes (ATC)
—
ATC code not specified
2
Mechanism of action (INN-stem analysis)
Monoclonal antibody (tumor, humanized)
1 substance
Unknown / small molecule
1 substance
Phase III:
1
Phase I (First in Human):
1
Phase III
1 trial-
RecruitingMerck Sharp & Dohme LLC CommercialSACITUZUMAB TIRUMOTECAN
Phase I (First in Human)
1 trial-
RecruitingDaiichi Sankyo Inc. CommercialDS-3939A
Sponsor activity
| Sponsor | Type | Trials | Phases | Recruiting |
|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Commercial | 1 | Phase III | 1 |
| Daiichi Sankyo Inc. | Commercial | 1 | Phase I (First in Human) | 1 |
New trials by year
2025
2